Boston, MA, November 09, 2016 --(PR.com
)-- Next-generation sequencing refers to modern non-Sanger-based high-throughput DNA sequencing technologies that can sequence millions or billions of DNA strands in parallel, yielding substantially more throughput and minimizing the need for the time consuming fragment-cloning methods that are often used in Sanger sequencing of genomes. Next-generation sequencing market is a fast emerging market with a high growth rate, as estimated by IQ4I Research that the Next-generation sequencing global market are expected to grow at a high double-digit CAGR from 2015-2022.
Reduced cost and high speed of NGS technology, increased usage in the clinical segment, new application areas of NGS and switch over from microarrays to NGS, are expected to propel the growth of next-generation sequencing market. However some issues like standardization of NGS for clinical use, complexity in data interpretation, shortage of skilled labor and dependence on grants and funding for NGS infrastructure may hinder the growth of next-generation sequencing market.
The Next-generation sequencing global market by technology is segmented into Reversible terminator sequencing, Ion semi-conductor sequencing, Sequencing by Ligation (SBL), Single-Molecule Real-time (SMRT) Sequencing and others. The Reversible terminator sequencing occupied highest market in Next-generation sequencing technology market. The Next-generation sequencing global market by products is segmented into Instruments, Services and Work-flow products. The services market is further segmented into Data analysis services and Sequencing Services. The Services segment is estimated to grow at strong CAGR from 2015 to 2022.
The Next-generation sequencing global market by Application is segmented based on process and field of application. By process, the market is segmented into Genomics, Epigenomics, Transcriptomics and others. Genomics application is further segmented into Whole genome sequencing, Exome sequencing, Targeted sequencing and De Novo sequencing). Epigenomics market is further segmented into ChiP sequencing and Methylation sequencing). By field of application, the market is segmented into Diagnostics, Drug discovery and development, Biomarker discovery, Agriculture and animal research and others. Diagnostics application is further segmented into Cancer diagnostics, Infectious disease diagnostics, Genetic analysis and Transplantation diagnostics. The Diagnostics application occupied highest market in Next-generation sequencing application market. The End-users consists of Academic Research, Hospitals and clinics, Biotech/Pharmaceuticals and Others. The Academic Research contributed the largest revenue as per estimates of IQ4I Research.
The Next-generation sequencing global market based on geography is divided into North America, Europe, Asia-Pacific and Rest of the world. North American region commanded the largest revenue in 2015 due to advanced technological healthcare framework, rise in growth of personalized medicine, increasing incidence of infectious disease and cancer, high R&D investment for genomic and proteomic sequence determination for biomarker and drug discovery research.
Some of the prominent players in next-generation sequencing market include Agilent Technologies (U.S.), BGI (China), Illumina, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Qiagen N.V. (Netherlands), Oxford Nanopore Technologies Ltd. (U.K.), Eurofins Scientific (U.K.), Roche holdings AG (Switzerland), DNASTAR, Inc. (U.S.), Thermo Fischer Scientific, Inc.(U.S).